Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell)
Drug Alias NameTGFbDNRII-transduced Autologous Tumor Infiltrating LymphocytesCD8-TCR-T cellsNY-ESO-1/CD8/HL AA2.1-19305dp-TCR-T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRoswell Park Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer Institute
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A